Chengdu Easton Biopharmaceuticals Co., Ltd. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 897.59 million compared to CNY 773.44 million a year ago. Net income was CNY 195.49 million compared to CNY 186.08 million a year ago.

Basic earnings per share from continuing operations was CNY 1.63 compared to CNY 1.55 a year ago. Diluted earnings per share from continuing operations was CNY 1.63 compared to CNY 1.55 a year ago.